Alison D Archibald
Biographic Data
| ID | 4218451 |
|---|---|
| NAME | Alison D Archibald |
| GIVEN NAMES | Alison D |
| FAMILY NAME | Archibald |
| SIGNATURE | ARCHIBALD A D |
| AFFILIATIONS | The University of Melbourne |
| ORCID | 0000-0002-4496-8262 |
| VERIFIED | Yes |
| TOTAL WORKS | 6 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 6 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2011 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Perinatal Genetic Screening From the Perspective of India-Born Individuals and Healthcare Providers in Victoria, Australia
Advances in genomic technologies are providing people with access to earlier diagnoses, intervention, and treatment of genetic conditions. However, there are inequities in access to and experiences of genomic technologies for several communities, such as people from non-European backgrounds and people who are born outside the country in which they reside. It is crucial to understand whether and how these issues manifest in different genomic healt…
How should severity be understood in the context of reproductive genetic carrier screening
Reproductive genetic carrier screening provides information about people's chance of having children with certain genetic conditions. Severity of genetic conditions is an important criterion for their inclusion in carrier screening programmes. However, the concept of severity is conceptually complex and underspecified. We analyse why severity is an important concept in carrier screening and for reproductive decision‐making and show that assessmen…
Exploring approaches to facilitate family communication of genetic risk information after cystic fibrosis population carrier screening
It gives them more options”
Development of a fragile X syndrome ( FXS ) knowledge scale
BACKGROUND: Genetic carrier screening is increasingly possible for many conditions, but it is important to ensure decisions are informed. The multidimensional measure of informed choice (MMIC) is a quantitative instrument developed to evaluate informed choice in prenatal screening for Down syndrome, measuring knowledge, attitudes and uptake. To apply the MMIC in other screening settings, the knowledge scale must be modified. OBJECTIVE: To develop…
Perceived relevance of genetic carrier screening
No prominent works on this page.
Perceived relevance of genetic carrier screening
Development of a fragile X syndrome ( FXS ) knowledge scale
BACKGROUND: Genetic carrier screening is increasingly possible for many conditions, but it is important to ensure decisions are informed. The multidimensional measure of informed choice (MMIC) is a quantitative instrument developed to evaluate informed choice in prenatal screening for Down syndrome, measuring knowledge, attitudes and uptake. To apply the MMIC in other screening settings, the knowledge scale must be modified. OBJECTIVE: To develop…
It gives them more options”
Exploring approaches to facilitate family communication of genetic risk information after cystic fibrosis population carrier screening
How should severity be understood in the context of reproductive genetic carrier screening
Reproductive genetic carrier screening provides information about people's chance of having children with certain genetic conditions. Severity of genetic conditions is an important criterion for their inclusion in carrier screening programmes. However, the concept of severity is conceptually complex and underspecified. We analyse why severity is an important concept in carrier screening and for reproductive decision‐making and show that assessmen…
Perinatal Genetic Screening From the Perspective of India-Born Individuals and Healthcare Providers in Victoria, Australia
Advances in genomic technologies are providing people with access to earlier diagnoses, intervention, and treatment of genetic conditions. However, there are inequities in access to and experiences of genomic technologies for several communities, such as people from non-European backgrounds and people who are born outside the country in which they reside. It is crucial to understand whether and how these issues manifest in different genomic healt…
Medicine (5 works) · Biology (4 works) · Cystic Fibrosis Research Advances (4 works) · Environmental health (4 works) · Family medicine (4 works) · Genetics (4 works) · Genetic testing (3 works) · Genetics and Neurodevelopmental Disorders (3 works) · Pathology (3 works) · Political science (3 works)